(NASDAQ: IRON) Disc Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.84%.
Disc Medicine's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast IRON's revenue for 2026 to be $407,242,953, with the lowest IRON revenue forecast at $407,242,953, and the highest IRON revenue forecast at $407,242,953. On average, 4 Wall Street analysts forecast IRON's revenue for 2027 to be $824,354,860, with the lowest IRON revenue forecast at $106,715,489, and the highest IRON revenue forecast at $1,251,454,622.
In 2028, IRON is forecast to generate $4,526,104,126 in revenue, with the lowest revenue forecast at $3,070,671,318 and the highest revenue forecast at $6,334,262,838.